The FDA has approved Tandem Diabetes Care’s Control-IQ+ automated insulin delivery technology for use during pregnancy in people with type 1 diabetes. The clearance, supported by the CIRCUIT trial, ...
MiniMed Group, Inc. (MiniMed; Nasdaq: MMED), a global leader in insulin delivery, announced Health Canada has licensed new ...
The FDA has cleared Tandem’s Control-IQ technology as the first ever AID specifically for use in pregnancies complicated by ...
Tandem Diabetes Care (Nasdaq:TNDM) today announced FDA clearance for its automated insulin delivery technology for use in ...
Glucagon-like peptide-1 receptor agonists, known as GLP-1 drugs, are highly effective at helping people lose weight and ...
In the long run, the new chip could enable next-generation wireless medical devices to maintain strong security even as quantum computing becomes more prevalent. In addition, it could be applied to ...
Recent research and clinical updates highlight how GLP-1 receptor agonists are transforming diabetes and obesity care, with expanding uses from adolescents with type 2 diabetes to off-label ...
Glooko, Inc., a globally integrated digital healthcare company focused on helping healthcare systems solve the growing ...
As technology becomes more integrated and personalized, experts say the biggest opportunity in diabetes management is ...
Managing type 2 diabetes can be challenging, especially when it comes to finding the right insulin dose. A new study suggests ...
The latest type 2 diabetes (T2D) management guidance from the American Association of Clinical Endocrinology (AACE) covers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results